EGFR and neoplasm: Overall, this study demonstrated that Formo acts as an inhibitor for the EGFR-Akt axis, and promotes FBW7-mediated Mcl-1 ubiquitination is required for the anti-tumor activity of Formo both in vitro and in vivo.